Navigation Links
Myriant Technologies LLC, Uhde Corporation of America and Uhde GmbH Announce Alliance for Engineering, Procurement & Construction of World Scale Renewable Succinic Acid Plants
Date:11/6/2009

QUINCY, Mass., Nov. 6 /PRNewswire/ -- Myriant Technologies LLC ("Myriant"), a privately-held, biotech developer and manufacturer of renewable bio-chemicals, Uhde Corporation of America and its preferred technology provider Uhde GmbH, one of the world's leading engineering contractors (jointly "Uhde"), announced an alliance for the engineering, procurement & construction (EPC) of Myriant's biobased Succinic Acid plants based on renewable feedstocks. The execution of this alliance marks an important milestone in Myriant's commercialization of biobased Succinic Acid and exemplifies Uhde's continued commitment to the renewable chemicals industry.

(Logo: http://www.newscom.com/cgi-bin/prnh/20091021/NE96331LOGO )

Myriant, which has successfully piloted the Succinic Acid process previously together with Uhde, has begun production of ton-sized samples for its customers to verify commercial product specifications and quality. The company expects to begin commercial production of biobased Succinic Acid second half of 2010.

Under Myriant's build-own-operate strategy, the alliance agreement combines the full breadth of Uhde's design and process expertise with Myriant's leading renewable, biobased Succinic Acid technology for the rapid deployment of full-scale commercial facilities. Uhde Corporation of America will be Myriant's engineering contractor for projects located in the U.S.; Uhde GmbH will act as Myriant's EPC Contractor in all other regions of the world. "The addition of Uhde's capabilities and experience is a perfect complement to Myriant's Succinic Acid program," said Stephen Gatto, Myriant Chairman and Chief Executive Officer. "Utilizing Uhde's unsurpassed EPC track record represents the final piece of the puzzle in making the construction of world scale biobased Succinic Acid plants a reality."

With more than 2,000 plants to its credit, Uhde GmbH is one of the world's leading engineering companies in the design and construction of chemical, refining and other industrial plants. "Uhde GmbH has built up special expertise in the field of biotechnology since 2004, and we are very excited about matching that expertise with Myriant's leadership position in Succinic Acid," stated Dr. Joachim Schulze, Head of Uhde GmbH's BioTechnology Division.

Succinic Acid has been recognized by both government organizations and the chemical industry as one of the most promising biochemicals that can be produced from renewable feedstocks to replace a wide range of petroleum-based chemicals. Myriant's renewable Succinic Acid offers cost competitive performance, reduced price volatility and a significantly enhanced environmental footprint as compared to petroleum-based alternatives. Given Succinic Acid's versatility, it can be used in a wide range of applications including polymers, solvents, pharmaceuticals, food and pigments. Typical end products that can utilize renewable Succinic Acid include car components, computer and electronic casings, shoe soles and paints.

Uhde GmbH has a workforce of more than 4,900 employees worldwide and is a company in the Plant Technology business area of the ThyssenKrupp Group. The company's activities focus on the engineering and construction of chemical and other industrial plants in the following fields: fertilisers; electrolysis; gas technologies; oil, coal and residue gasification; refining technologies; organic intermediates, polymers and synthetic fibres; and also coke plant and high-pressure technologies. "We also provide our customers with professional services and comprehensive solutions in all areas of industrial plant operation. Details are available at www.uhde.eu"

With a world-renowned team of molecular biologists, engineers and chemists, Myriant utilizes proprietary technology to advance the development of low-cost cellulosic sugars for the sustainable commercialization of high-value specialty chemicals. The company's D(-) lactic acid started production at commercial scale in June 2008 for use in polylactic acid. Myriant is headquartered in Quincy, Massachusetts. Details are available at www.myriant.com.

    Contacts:
    Myriant - Samuel G. McConnell, Sr. VP, Corporate Development
    (617) 657-5207
    Uhde Corporation of America - Dr. Dennis Lippmann, Managing Director
    (412) 257-8277
    Uhde GmbH - Dr. Joachim Schulze, Head of BioTechnology Division
    +49 (3 41) 9 89-74612
       Dr. Detlef Markmann, Head of Corporate Communications
       +49 (2 31) 5 47-3813

SOURCE Myriant Technologies LLC


'/>"/>
SOURCE Myriant Technologies LLC
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Myriant Technologies LLC Announces Appointment of Science Advisory Board Members
2. BioEnergy International, LLC Announces Formation of Myriant Technologies LLC
3. BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results
4. MarketsandMarkets: Global Stem Cell and Advanced Technologies Market Worth US$ 88.3 Billion By 2014
5. BioSpecifics Technologies Corp. to Host Conference Call to Report Third Quarter 2009 Financial Results on November 5, 2009
6. TOPAZ Technologies Announces SoBran Inc. as New Customer
7. Precision Antibody Wins Contract to Develop Gold Standard Antibodies as Part of National Cancer Institutes Clinical Proteomics Technologies for Cancer (CPTC) Initiative
8. China Medical Technologies to Exhibit its Products at China International Medical Equipment Fair in Chengdu, China
9. Epeius Biotechnologies to Partner at BIO Investor Forum
10. Neurobiological Technologies Announces Intent to File Form 25 to Delist Common Stock From the NASDAQ Capital Market
11. OriGene Technologies Acquires Marligen Biosciences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... ... 2016 , ... Global Stem Cells Group, has ... The new facility will provide advanced protocols and state-of-the-art techniques in cellular medicine, ... , The new GSCG clinic is headed by four prominent Ecuadorian physicians, including ...
(Date:2/10/2016)... WASHINGTON , February 10, 2016 Early-career ... , Peru , Uganda ... their life-enhancing work in health and nutrition   Indonesia ... Uganda and Yemen are ... sciences and epidemiology. They are also celebrated for mentoring young women scientists ...
(Date:2/10/2016)... LOUISVILLE, Ky. , Feb. 10, 2016 ... company utilizing its proprietary NeXosome® technology for early ... presentation of its most recent study by Dr. ... Hospital at the Society for Maternal Fetal Medicine,s (SMFM) ... , GA, February 1-6 th , 2016.  The presentation ...
(Date:2/10/2016)... , ... February 10, 2016 ... ... today announced that it has joined the Human Vaccines Project, a public-private ... diseases and cancer. , The Human Vaccines Project brings together leading ...
Breaking Biology Technology:
(Date:2/1/2016)... 2016  Today, the first day of American Heart ... develop a first of its kind workplace health solution ... In the first application of Watson ... ), and Welltok will create a new offering that ... analytics, delivered on Welltok,s health optimization platform. The effort ...
(Date:1/28/2016)... 28, 2016 Synaptics (NASDAQ: SYNA ), a leading ... second quarter ended December 31, 2015. --> ... fiscal 2016 increased 2 percent compared to the comparable quarter last ... fiscal 2016 was $35.0 million, or $0.93 per diluted share. ... for the first quarter of fiscal 2016 grew 9 percent over ...
(Date:1/25/2016)... --  Unisys Corporation (NYSE: UIS ) today announced the ... Airport, New York City , to help ... enter the United States using passports that ... testing of the system at Dulles last year. The system ... January 2016. --> pilot testing of the system ...
Breaking Biology News(10 mins):